AUPH News and Press, Aurinia Pharmaceuticals Inc From 08/03/23

2023-08-03 06:02:12 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11 . Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M . Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ...

Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ® (voclosporin) Conference call to be hosted today at 8:30 a.m...

2023-08-02 13:39:36 ET Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus Revenue Estimate is $37.51M (+33.0% Y/Y). Over the last ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:3...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology , the official peer-reviewed journal of the American College...

2023-07-18 12:50:45 ET Summary Aurinia Pharmaceuticals has reported increased Q1 2023 net revenue of $34.4 million, largely due to higher sales of its Lupus Nephritis drug, Lupkynis. However, the company also recorded a net loss of $26.2 million. The company is exploring strategic...

2023-06-30 14:49:03 ET Shares of the autoimmune specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) rose by as much as 13.2% in early morning trading Friday. The biotech's shares cooled off after their hot start and are up by 8.6% on heavy volume as of 1:41 p.m. ET Friday. The sto...

2023-06-30 14:47:04 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) could see prices in the high $20s to low $30s per share in a takeout at premium multiples, according to RBC, after the company announced Thursday it was exploring alternatives. Aurinia ( AUPH ) rose 9.1%. ...

In Addition, Board has Accepted Recent Director Resignations and has Initiated a Search for New Directors Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has initiated an exploration of stra...

LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with mycophenolate mofetil and low-dose steroids alone, in a pooled, post-hoc analysis. 1 LUPKYNIS...